RxDoctor Payments Data

Karalyn Champion

Family · Fresno, CANPI 1124403159

Payments from drug & device makers

$3,609in general payments, 2019–2025

Across 184 payments — averaging $19.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$497
  • Sanofi$367
  • Medtronic$324
  • Boehringer Ingelheim$264
  • Xeris Pharmaceuticals, Inc.$223
  • Novo Nordisk$215
  • plus $2K from 21 others

What the payments were for

  • Travel & lodging$471%
  • Food & beverage$3,56399%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,609 in reported general payments places this provider in the 90th percentile of 10,634 family providers in California.

See all family providers in California

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide537$609,871
OzempicSemaglutide291$316,831
JardianceEmpagliflozin247$176,141
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog142$125,224
Tresiba Flextouch U-200Insulin Degludec96$76,933
FarxigaDapagliflozin Propanediol70$62,063
TrulicityDulaglutide37$48,477
Humalog Kwikpen U-200Insulin Lispro24$26,439
RybelsusSemaglutide25$25,073
Gvoke Hypopen 2-PackGlucagon31$21,517
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog29$16,380
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/719$15,318
Humalog Kwikpen U-100Insulin Lispro57$14,996
Tresiba Flextouch U-100Insulin Degludec30$14,799
Novolog FlexpenInsulin Aspart68$14,496

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro$168$668,544636 claims
Novo NordiskOzempic, Rybelsus, Novolog$215$347,850335 claims
Boehringer IngelheimJardiance$264$176,141247 claims
AstraZenecaFarxiga$104$62,06370 claims
Sanofi-aventis U.S. LLCLantus$60$4,42138 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,634 family providers in California.

Other family in Fresno

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →